drugset / Trial / NCT01082562

Safety Study of BMS-844421 for Treatment of Hypercholesterolemia

NCT01082562 ↗

Phase 1 Terminated 40 enrolled Bristol-Myers Squibb
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the safety, tolerability, serum concentrations and pharmacodynamic effects on serum low-density lipoprotein (LDL) cholesterol of single and multiple subcutaneous and intravenous doses of BMS-844421 in healthy subjects (SAD) and in subjects with elevated cholesterol (MAD).

Timeline

Start
2010-04
Primary completion
2010-07
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject BMS-844421 Unknown 37.5 mg Subcutaneous